Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: Lancet Oncol. 2018 Sep 17;19(10):1351–1359. doi: 10.1016/S1470-2045(18)30487-X

Table 2:

Efficacy

Overall Response Rate Number of patients (%)
Total Evaluable 31 (100)
CR 0
PR 13 (42)
SD 18 (58)
PD 0
Inevaluable 1
Response by Organ Site Number of sites (%)
Renal Central System Nervous Pancreas
#Target Lesions 59(100) 49(100) 17(100)
CR (%) 2 (3) 0 0
PR (%) 29 (49) 2 (4) 9 (53)
SD (%) 28 (47) 47 (96) 8 (47)
PD (%) 0 0 0